Dismissing the fallacies of childhood eczema management: case scenarios and an overview of best practices

Kam Lun Hon MBBS, MD (CUHK), FAAP, FCCM, Kin Fon Leong MBBS, MRCPCH, Theresa Leung MBBS, FRCPCH, FHKAM(Paed), FHKCPaed, Alexander KC Leung MBBS, FRCPC, FRCP(UK & Irel), FRCPCH, FAAP

Abstract

Background: Eczema or atopic dermatitis (AD) is a common relapsing childhood dermatologic illness. Treatment of AD is primarily topical with emollients and corticosteroid/calcineurin inhibitor, which is efficacious for the majority of patients. However, AD is often complicated and difficult to manage in many Asian cities. Effective therapy is impeded by fallacies in the following aspects: (1) mistrust and unrealistic expectations about Western medicine, (2) skin care and allergy treatment, (3) ambiguity about optimal bathing and moisturizing, (4) hesitation and phobias about the usage of adequate topical corticosteroid and immunomodulatory therapies, (5) food and aeroallergen avoidance and dietary supplementation, and (6) complementary and alternative therapies.

Methods and Results: Eleven anonymized case scenarios are described to illustrate issues associated with these fallacies. A literature review is performed and possible solutions to handle or dismiss these fallacies are discussed.

Conclusions: The first step in patient care is to accurately assess the patient and the family to evaluate possible concerns, anxiety, and phobias that could impede therapeutic efficacy. Education about the disease should be individualized. Conflicting recommendations on the usage of topical steroid have a detrimental effect on management outcomes, which must be avoided.

Article Details

Article Type

Review

DOI

10.7573/dic.212547

Categories

Publication Dates

Accepted: ; Published: .

Citation

Hon KL, Leong KF, Leung TNH, Leung AKC. Dismissing the fallacies of childhood eczema management: case scenarios and an overview of best practices. Drugs in Context 2018; 7: 212547. DOI: 10.7573/dic.212547

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.